Calcif Tissue Int 58:395–397PubMed”
“Erratum to: Osteoporos<

Calcif Tissue Int 58:395–397PubMed”
“Erratum to: Osteoporos

Int DOI 10.1007/s00198-010-1513-x The affiliation of the authors M. Berry, C. Watson and J. Wilkinson was rendered incorrectly. The correct affiliation is shown here.”
“Introduction Postmenopausal women with osteoporosis have an increased risk of fracture and its associated complications, such as back pain and disability/functional impairment, which can lead to a reduced health-related quality of life (HRQoL) [1–9]. Clinical vertebral and hip fractures are also associated with increased mortality [10, 11]. Treatment aims to reduce the risk, incidence and burden of osteoporosis-related MK5108 price fractures. Teriparatide, a recombinant human N-terminal fragment of parathyroid hormone (rhPTH 1–34), is a bone anabolic agent that increases bone mass and strength. In a placebo-controlled trial, daily teriparatide treatment for Sotrastaurin in vivo 19 months reduced the risk of vertebral and non-vertebral fractures in postmenopausal women with severe osteoporosis [12]. Teriparatide is approved for a limited treatment duration and is typically used as a second-line treatment option in postmenopausal women with severe osteoporosis. Thus, many patients receiving teriparatide have previously been treated with antiresorptive therapies and require further osteoporosis

medication after teriparatide is discontinued. However, there is limited published data on the use of teriparatide as a sequential treatment for osteoporosis, particularly in a real-life clinical practice setting. Most previous studies reporting the selleck products effects of teriparatide in postmenopausal women have been controlled clinical trials with strict inclusion criteria and highly selected patient populations; patients with co-morbidities, such

as rheumatoid arthritis, and those taking concomitant medications are often excluded. It has been estimated that about 80% of patients receiving treatment for osteoporosis would not be eligible for inclusion in a randomised controlled trial [13]. Since observational studies have few exclusion criteria, they can investigate treatment effects in a broader range of patients in the routine care setting, and can provide valuable supporting information that is applicable in clinical practice [14]. No previous observational studies have examined the effectiveness and safety of teriparatide during and after treatment. The European Forsteo Observational Study (EFOS) was a 36-month, prospective, observational study designed to evaluate fracture outcomes, back pain and HRQoL in postmenopausal women with severe osteoporosis treated with teriparatide in the outpatient setting for a maximum of 18 months, followed by a post-teriparatide treatment period of a further 18 months. We report here the main study analyses for the total study cohort followed up for 36 months, i.e.

Comments are closed.